Across TCGA pan-cancer cohorts, TRAV17 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TRAV17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAV17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV17 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.

KIRC, LUSC, and BRCA are the cancer types where TRAV17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAV17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.292	<.001	11	view →
LUSC	Male	III,IV	−1.150	.010	4	view →
BRCA	All	All	+0.292	.011	4	view →
COAD	Female	IV	−1.070	.030	1	view →
CHOL	Female	All	+0.906	.003	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRAV17 RNA expression & survival · all TRAV17 data types